Repare Therapeutics Inc. announced an exclusive worldwide licensing agreement with Debiopharm International S.A. for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. This agreement builds on an existing collaboration between the two companies.
Under the terms, Repare will receive a $10 million upfront payment and is eligible for up to $257 million in potential clinical, regulatory, commercial, and sales milestones, including up to $5 million in near-term payments. Repare will also receive single-digit royalties on global net sales.
Debiopharm will assume sponsorship of the MYTHIC study and take over all existing and future development activities related to lunresertib. This allows Repare to focus its resources on advancing its two ongoing Phase 1 clinical trials, POLAR (RP-3467) and LIONS (RP-1664), with readouts expected in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.